Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

Published:2013 Issue:1 Volume:85 Page:8-13
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Maj-Hes Agnes,Medioni Jacques,Scotte Florian,Schmidinger Manuela,Kramer Gero,Combe Pierre,Gornadha Yohan,Elaidi Reza,Oudard Stéphane

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma;Cancers;2023-06-12

2. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options;Cancers;2022-11-18

3. Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction;Cancers;2021-02-02

4. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report;Tumori Journal;2020-05-27

5. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma;Current Oncology Reports;2016-09-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP